I Cell Disease News and Research

RSS

Researchers develop C6 compound that prevents abnormalities linked with priapism in mice

It's not the little blue pill famous for helping men get big results, but for those who need it, the outcome might be even more significant. A new research report published online in The FASEB Journal, offers hope to men who experience priapism. This condition, which is often seen in men with sickle cell disease, causes erections lasting so long that they cause permanent damage to the penis.

1 Oct 2013

Parenting stress among caregivers of children with chronic illness: A systematic review

The extra demands on parents of chronically ill children cause stress that affects the whole family, according to a systematic review conducted by Case Western Reserve University researchers that also explored what factors in the child's care most contribute to the added strain.

19 Sep 2013

Arginine therapy may be safe treatment for patients with sickle cell disease

Arginine therapy may be a safe and inexpensive treatment for acute pain episodes in patients with sickle cell disease, according to results of a recent clinical study. The study was the first randomized placebo-controlled study to demonstrate benefits of arginine therapy in children with sickle cell disease hospitalized for severe pain.

17 Sep 2013

Four new pre-clinical drug development projects at NIH develop treatment for rare disease

Four new pre-clinical drug development projects at the National Institutes of Health will target a form of blindness and diseases characterized by cardiac problems. The projects were selected for their potential to treat specific rare diseases and to help scientists uncover new information that can be shared with other researchers.

13 Sep 2013

Hydroxyurea treatment prevents complications, lowers medical care costs in children sickle cell disease

The benefits of hydroxyurea treatment in people with sickle cell disease are well known -- fewer painful episodes, fewer blood transfusions and fewer hospitalizations. Now new research from the Johns Hopkins Children's Center and other institutions reveals that by preventing such complications, the drug can also considerably lower the overall cost of medical care in children with this condition.

12 Sep 2013

UCLA researchers receives $13M Early Translational grants to advance innovative discoveries using stem cells

Four researchers from UCLA's Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have received Early Translational Research Awards totaling approximately $13 million from the California Institute for Regenerative Medicine, the state's stem cell agency. The UCLA researchers received four of the 12 total awards; no other institution received more than one.

4 Sep 2013

Chronic granulomatous disease (CGD) research: an interview with Dr. Griffin Rodgers, NIDDK director

Chronic granulomatous disease, or CGD, is a diverse group of inherited diseases in which certain cells of the immune system have difficulty forming reactive oxygen compounds, most importantly superoxide radicals. These are used by these white blood cells to kill certain bacteria.

3 Sep 2013

Drug for children with sickle cell anemia reduces hospitalizations and treatment costs

A drug proven effective for treatment of adults and children with sickle cell anemia reduced hospitalizations and cut annual estimated medical costs by 21 percent for affected infants and toddlers, according to an analysis led by St. Jude Children's Research Hospital. The report appears today in the advance online edition of the journal Pediatrics.

2 Sep 2013

Stem cell researchers receive Early Translational research awards from CIRM

Four prominent researchers from UCLA's Eli & Edythe Broad Center of Regenerative Medicine and Stem Cell Research have received Early Translational research awards totaling approximately $13 million from the California Institute for Regenerative Medicine (CIRM) the state stem cell agency. The UCLA researchers received four of the 12 total awards; no other applicant institution received more than one award.

30 Aug 2013

Pre-doctoral students receive International Student Research Fellowships from HHMI

The Howard Hughes Medical Institute has awarded two doctoral students from the Sackler School of Graduate Biomedical Sciences at Tufts University with 2013 International Student Research Fellowships. Seblewongel Asrat, from Ethiopia, studies the bacterium that causes Legionnaires' disease while Jennifer Nwankwo, from Nigeria, studies red blood cell dehydration in sickle cell disease.

17 Aug 2013

Miniscule signaling molecule plays critical role in certain acute and chronic diseases

Scientists seeking to harness the healing power of a miniscule signaling molecule that plays a critical role in certain acute and chronic diseases have been awarded a Program Project Grant (PPG) of nearly $10 million by the National Heart, Lung and Blood Institute of the National Institutes of Health.

1 Aug 2013

UCLA researchers introduce gene therapy technique to treat sickle cell disease

Researchers at UCLA's Eli & Edythe Broad Center of Regenerative Medicine & Stem Cell Research have successfully established the foundation for using hematopoietic (blood-producing) stem cells from the bone marrow of patients with sickle cell disease to treat the disease.

2 Jul 2013

TSRI scientists identify small molecules to control genetic defect responsible for muscular dystrophy

For the first time, scientists from the Florida campus of The Scripps Research Institute have identified small molecules that allow for complete control over a genetic defect responsible for the most common adult onset form of muscular dystrophy.

28 Jun 2013

Study finds decrease in risk of death from ischemic stroke in US black children

The excess risk of death from ischemic (due to reduced blood flow), but not hemorrhagic (due to bleeding), stroke in US black children has decreased over the past decade, according to a study by Laura L. Lehman, M.D., of Boston Children's Hospital, and colleagues.

25 Jun 2013

Researchers to launch Phase II clinical trial to investigate potential new therapy for sickle cell anemia

Seeking to improve the lives of sickle cell anemia sufferers around the world, researchers from the La Jolla Institute for Allergy and Immunology, the Dana-Farber/Children's Hospital Cancer Center in Boston and the BloodCenter of Wisconsin in Milwaukee and others are preparing to launch Phase II of a clinical trial to investigate a potential new therapy for reducing the disorder's severest symptoms.

12 Jun 2013

Cerus enrolls patient in two European clinical trials for INTERCEPT System for RBCs

Cerus Corporation announced today that it has initiated patient enrollment in two European Phase III clinical trials for the INTERCEPT System for red blood cells.

11 Jun 2013

Duke researchers find novel way to repair gene responsible for Duchenne muscular dystrophy

Using a novel genetic 'editing' technique, Duke University biomedical engineers have been able to repair a defect responsible for one of the most common inherited disorders, Duchenne muscular dystrophy, in cell samples from Duchenne patients.

5 Jun 2013

Novel approach to create unlimited number of human red blood cells, platelets in vitro

A study led by Boston University School of Medicine has identified a novel approach to create an unlimited number of human red blood cells and platelets in vitro. In collaboration with Boston University School of Public Health and Boston Medical Center, the researchers differentiated induced pluripotent stem cells into these cell types, which are typically obtained through blood donations.

31 May 2013

Clinical Research Forum selects sickle cell project among 'Top 10' clinical research achievements of 2012

Pioneering research led by Johns Hopkins scientists on the use of partially matched bone marrow transplants to wipe out sickle cell disease has been selected as one of the Top 10 Clinical Research Achievements of 2012 by the Clinical Research Forum.

22 Apr 2013

New combination therapies with anti-sickling capabilities needed for sickle cell disease

Pain is an undeniable focal point for patients with sickle cell disease but it's not the best focus for drug development, says one of the dying breed of physicians specializing in the condition.

18 Apr 2013